Kura Oncology Files 8-K
Ticker: KURA · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $30 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, other-events
Related Tickers: KURA
TL;DR
Kura Oncology filed an 8-K, but details are scarce.
AI Summary
Kura Oncology, Inc. filed an 8-K on October 24, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a significant event has occurred for Kura Oncology, requiring immediate disclosure to investors, though the specifics are not yet detailed.
Risk Assessment
Risk Level: medium — The lack of specific information in the 8-K creates uncertainty for investors, necessitating further investigation.
Key Players & Entities
- Kura Oncology, Inc. (company) — Registrant
- October 24, 2025 (date) — Filing Date
- 4930 Directors Place, Suite 500 (location) — Principal Executive Offices
- San Diego, CA (location) — Principal Executive Offices City/State
- 92121 (location) — Principal Executive Offices Zip Code
- (858) 500-8800 (phone_number) — Registrant's Telephone Number
FAQ
What specific event(s) are being reported under "Other Events"?
The filing does not specify the nature of the "Other Events" beyond the general categorization.
Are there any financial implications or dollar amounts associated with the reported event?
The provided text of the 8-K does not mention any specific dollar amounts or financial figures related to the reported event.
When did the event(s) prompting this 8-K filing occur?
The earliest event reported is dated October 24, 2025, which is also the filing date.
Does this filing relate to any new product development, clinical trial results, or regulatory updates for Kura Oncology?
The filing categorizes the event as "Other Events" and does not provide details on product development, trials, or regulatory matters.
Is there any information about potential mergers, acquisitions, or significant partnerships mentioned in this filing?
The filing does not contain any information regarding mergers, acquisitions, or partnerships.
Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-10-24 07:24:52
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se
- $30 million — the " Company ") announced receipt of a $30 million milestone payment under its Collaborati
Filing Documents
- d939392d8k.htm (8-K) — 22KB
- 0001193125-25-249348.txt ( ) — 133KB
- kura-20251024.xsd (EX-101.SCH) — 3KB
- kura-20251024_lab.xml (EX-101.LAB) — 18KB
- kura-20251024_pre.xml (EX-101.PRE) — 11KB
- d939392d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kura Oncology, Inc. Date: October 24, 2025 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer